UK says it won't pur­chase As­traZeneca's Covid treat­ment due to 'in­suf­fi­cien­t' Omi­cron da­ta — re­ports

Weeks af­ter ev­i­dence sug­gest­ed cur­rent Omi­cron sub­vari­ants may be less sus­cep­ti­ble to As­traZeneca’s pro­phy­lac­tic Covid-19 treat­ment Evusheld, the UK has re­port­ed­ly de­cid­ed against buy­ing dos­es for now.

The UK’s De­part­ment of Health said it won’t pro­cure Evusheld dos­es due to “in­suf­fi­cient da­ta on the du­ra­tion of pro­tec­tion of­fered by Evusheld in re­la­tion to the omi­cron vari­ant,” ac­cord­ing to the BMJ, a peer-re­viewed trade jour­nal pub­lished by the British Med­ical As­so­ci­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER